A cewar wani gwaji na asibiti da yawa wanda masu bincike a Makarantar Medicine na Jami'ar Stanford suka jagoranta, wani sabon nau'in immunotherapy yana da alama yana da lafiya ga marasa lafiya da ciwon daji na jini da ake kira lymphoma ba Hodgkin.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of lymphoma ba Hodgkin: diffuse large B- cell lymphoma and follicular lymphoma.
A cikin 2010, masu bincike karkashin jagorancin Irving Weissman, MD, darektan Stanford Stem Cell Biology da Regenerative Medicine Institute, sun nuna cewa kusan dukkanin kwayoyin cutar kansa an rufe su da furotin da ake kira CD47, wanda zai iya wasa “kada ku ci ni” Sigina zuwa macrophages.
Weissman da abokan aikinsa daga baya sun kirkiro wani maganin rigakafi mai suna Hu5F9-G4 wanda ke toshe furotin CD47 kuma yana ƙarfafa macrophages don mamaye ƙwayoyin cutar kansa. Rituximab wani maganin rigakafi ne wanda aka nuna don haɓaka siginar "ci ni". Haɗin rituximab da Hu5F-G4 a baya an nuna cewa suna da tasiri a kan cutar kansar ɗan adam a cikin nau'ikan dabbobi, amma wannan shine farkon da aka buga sakamakon gwajin asibiti na jiyya a cikin ɗan adam.
Daga cikin marasa lafiya 22 da ke halartar gwajin, marasa lafiya 11 sun rage ciwon daji na asibiti sosai, kuma marasa lafiya 8 sun kawar da dukkan alamun cutar kansa. Sauran marasa lafiya uku da ke cikin gwajin ba su amsa magani ba kuma sun mutu saboda ci gaban cutar. Masu binciken sun lura cewa mahalartan suna da illa kaɗan.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunotherapy is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
